Monday, June 5, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Health Sciences Clinical Professor of Family Medicine
University of California, Irvine School of Medicine
Irvine, California
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for primary care clinicians, gastroenterologists, oncologists, nurses, physician assistants, nurse practitioners, and other clinicians who treat and manage younger adults at risk for colorectal cancer.
The goal of this activity is for members of the healthcare team to be better able to analyze potential risk factors and pathological processes for early-onset colorectal cancer.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Health Sciences Clinical Professor of Family Medicine
University of California, Irvine School of Medicine
Irvine, California
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 4/21/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 4/21/2023
Valid for credit through: 4/21/2024
processing....
The epidemiology of colorectal cancer (CRC) is shifting, and no group is experiencing a faster increase in the number of cases of CRC than persons younger than 50 years. The prevalence of CRC in this age demographic has been rising by 2% to 4% per year for more than 2 decades, and it has increased even more steeply among individuals younger than 30 years. On the basis of these trends, CRC is expected to become the leading cause of cancer-related mortality among adults between the ages of 20 and 49 years by 2030.
Early-onset CRC has some unique clinical features compared with CRC diagnosed after age 50 years. Sadly, metastatic early-onset CRC is not associated with a better prognosis, despite younger patients having fewer comorbidities and better functional status. The current review highlights some the clinical features on early-onset CRC and why its prevalence is increasing.
Although rates of CRC are on the decline, the incidence among younger people continues to rise.
Data show that the incidence of early-onset CRC, diagnosed in people younger than 50, has increased globally by as much as 2% to 4% a year since the 1990s, with even steeper increases among those younger than 30.
“We know rates are increasing in young people, but it’s alarming to see how rapidly the whole patient population is shifting younger, despite shrinking numbers in the overall population,” Rebecca Siegel, MPH, of the American Cancer Society and lead author of a new report published in March 2023 that highlights this trend, said in a statement.[1]
But gaining a more granular understanding of why this shift is occurring remains a challenge. Studies attempting to unravel the causes of early-onset CRC have been limited in scope, often focusing on single aspects of the etiology, whereas the causes are likely multifactorial, according to Marios Giannakis, MD, PhD, and Kimmie Ng, MD, PhD, from the Young-Onset Colorectal Cancer Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts.
That is why “[a] multidisciplinary path forward is needed to expand the understanding of this increasingly prevalent problem,” Dr Giannakis and Dr Ng write in a perspective published in Science, in which they summarize the current state of our understanding.[2]
In their perspective, Dr Giannakis and Dr Ng highlight several patterns that have emerged among individuals with early-onset CRC.
Younger patients are often diagnosed at more advanced stages of disease, despite having fewer comorbidities. This pattern could stem from a lack of screening to detect early lesions, but it “also raises the question of a more aggressive biology,” Dr Giannakis and Dr Ng write.
This idea is supported by the fact that survival rates among younger patients with metastatic early-onset CRC are similar to those among older patients, despite the fact that younger patients are often healthier overall, they undergo more intensive therapy, and they experience fewer adverse effects from treatment.
What might be happening on a genetic level in younger patients?
The evidence to date suggests that factors that predispose to cancer are more prevalent among younger patients. The most common such factor is Lynch syndrome. However, underdiagnosis of Lynch syndrome and high-penetrance pathogenic germline variants “do not explain the observed rise of [early-onset CRC],” the perspective authors note.
Tumors also tend to present on the left side of the colon and rectum. Symptoms include abdominal pain and rectal bleeding. Left-sided tumors have different embryologic origins and may provide clues to the mutational profiles of early-onset tumors. But large, genome-wide association studies dedicated to early-onset CRC as well as “analyses of gene-environment interactions are needed to further refine any genetic contribution that is specific to young-onset presentation,” the authors note.
On the environmental and lifestyle fronts, Dr Giannakis and Dr Ng highlight the roles obesity and other metabolic conditions, as well as physical inactivity and diet, may play in early-onset CRC risk.
One 2019 study, for instance, found that obesity during adolescence and adulthood was associated with a higher risk for early-onset CRC.[3] Another study, published the same year, revealed that being more sedentary may increase the risk for early-onset CRC.[4] Consumption of sugar-sweetened beverages and red and processed meat have been implicated in the early emergence of CRC as well.[5,6]
These factors can affect an individual’s gut microbiome, which is yet another probable player in early-onset CRC. There is a “compelling body of evidence supporting a role of the gut microbiota in CRC pathogenesis and progression, including species such as Fusobacterium nucleatum, Bacteroidetes fragilis, and pks+ E coli,” the authors say.
Although complex, understanding the interactions between lifestyle and dietary elements, the tumor microenvironment, and the host “will be fundamental to uncovering the root causes of the rise in [early-onset CRC],” Dr Giannakis and Dr Ng explain.
What steps can help map out a path forward?
Recent recommendations by the American Cancer Society and the US Preventive Services Task Force to start CRC screening for the average population at age 45 years represent a step in the right direction, but the path forward “is neither short nor straightforward.”
To meet the challenges, Dr Giannakis and Dr Ng propose developing specialized centers of excellence that are focused on patients with early-onset disease to provide and model comprehensive clinical care and conduct multidisciplinary research.
Global collaborations and prospective cohort studies of healthy individuals and patients with early-onset CRC are needed as well. The Count Me In Colorectal Cancer Project, for instance, partners with patients in the US and Canada and makes data available for research.
“The urgency of navigating this path, which goes beyond unidimensional perspectives and considers the multifactorial nature of [early-onset CRC], is paramount, particularly for the youngest patients who do not meet the recommended screening age,” Dr Giannakis and Dr Ng conclude.
Dr Giannakis has received research funding from Janssen and Servier. Dr Ng has received institutional research funding from Pharmavite, the Evergrande Group, Janssen, and Revolution Medicines and advisory or consulting fees from Bayer, GlaxoSmithKline, and Pfizer.
Science. Published March 16, 2023.
